Table 1.
Patient Characteristics in the 3 DOAC Groups
| Dabigatran | Rivaroxaban | Apixaban | |
|---|---|---|---|
| Dose* | 110 mg: 10 (39%) | 15 mg: 2 (7%) | 2.5 mg: 13 (41%) |
| 150 mg: 16 (62%) | 20 mg: 28 (93%) | 5 mg: 19 (59%) | |
| Sex, female* | 13 (50%) | 13 (43%) | 15 (47%) |
| Age, y† | 74±14 | 69±15 | 75±13 |
| Body weight, kg† | 80±23 | 80±19 | 72 ±15 |
| Body mass index† | 27±6 | 27±6 | 25±4 |
| Risk factors | |||
| Arterial hypertension* | 20 (77%) | 19 (63%) | 27 (84%) |
| Diabetes mellitus* | 6 (23%) | 5 (17%) | 8 (25%) |
| Hyperlipidemia* | 15 (58%) | 7 (23%) | 17 (53%) |
| Smoking* | 2 (8%) | 4 (13%) | 3 (9%) |
| Concomitant antiplatelet agents (last dose <7 d) | |||
| Acetylsalicylic acid* | 7 (27%) | 15 (50%) | 15 (47%) |
| Others* | 0 (0%) | 1 (3%) | 1 (3%) |
| Prophylactic dose of heparins at any time during admission | |||
| Heparin* | 19 (73%) | 20 (67%) | 23 (72%) |
| Enoxaparin* | 6 (23%) | 14 (47%) | 12 (38%) |
| Indication for oral anticoagulation | |||
| Atrial fibrillation* | 24 (92%) | 21 (70%) | 15 (47%) |
| Patent foramen ovale* | 2 (8%) | 9 (30%) | 0 (0%) |
| ESUS* | 0 (0%) | 0 (0%) | 17 (53%) |
DOAC indicates direct oral anticoagulants; ESUS, embolic stroke of undetermined source.
* Number (%), †mean±SD.